{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T21:47:54Z","timestamp":1791668874704,"version":"4.3.4"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T00:00:00Z","timestamp":1740355200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T00:00:00Z","timestamp":1740355200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001352","name":"National University of Singapore","doi-asserted-by":"crossref","award":["NUHSRO\/2020\/133\/Startup\/08"],"award-info":[{"award-number":["NUHSRO\/2020\/133\/Startup\/08"]}],"id":[{"id":"10.13039\/501100001352","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1007\/s00259-025-07155-9","type":"journal-article","created":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T06:47:42Z","timestamp":1740379662000},"page":"2841-2855","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Development of [225Ac]Ac\u2011LNC1011 for targeted alpha-radionuclide therapy of prostate cancer"],"prefix":"10.1007","volume":"52","author":[{"given":"Xuejun","family":"Wen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianzhi","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongzhang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengqi","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin Jie","family":"Wee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayu","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenyue","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maosheng","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Green","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoming","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9622-0870","authenticated-orcid":false,"given":"Xiaoyuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,24]]},"reference":[{"key":"7155_CR1","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","volume":"385","author":"O Sartor","year":"2021","unstructured":"Sartor O, de Bono J, Chi KN, Fizazi K, Herrmann K, Rahbar K, et al. Lutetium-177-PSMA-617 for metastatic castration-resistant prostate Cancer. N Engl J Med. 2021;385:1091\u2013103. https:\/\/doi.org\/10.1056\/NEJMoa2107322.","journal-title":"N Engl J Med"},{"key":"7155_CR2","doi-asserted-by":"publisher","first-page":"769","DOI":"10.5534\/wjmh.220200","volume":"41","author":"K Hatano","year":"2023","unstructured":"Hatano K, Nonomura N. Systemic therapies for metastatic castration-resistant prostate Cancer: an updated review. World J Mens Health. 2023;41:769\u201384. https:\/\/doi.org\/10.5534\/wjmh.220200.","journal-title":"World J Mens Health"},{"key":"7155_CR3","doi-asserted-by":"crossref","first-page":"13n","DOI":"10.2967\/jnumed.121.263195","volume":"63","author":"FDA Approves Pluvicto","year":"2022","unstructured":"FDA Approves Pluvicto. Locametz for metastatic castration-resistant prostate Cancer. J Nucl Med. 2022;63:13n.","journal-title":"J Nucl Med"},{"key":"7155_CR4","doi-asserted-by":"publisher","first-page":"LBA4","DOI":"10.1200\/JCO.2021.39.15_suppl.LBA4","volume":"39","author":"MJ Morris","year":"2021","unstructured":"Morris MJ, Bono JSD, Chi KN, Fizazi K, Herrmann K, Rahbar K, et al. Phase III study of lutetium-177-PSMA-617 in patients with metastatic castration-resistant prostate cancer (VISION). J Clin Oncol. 2021;39:LBA4\u2013LBA. https:\/\/doi.org\/10.1200\/JCO.2021.39.15_suppl.LBA4.","journal-title":"J Clin Oncol"},{"key":"7155_CR5","doi-asserted-by":"publisher","first-page":"422","DOI":"10.7150\/thno.68182","volume":"12","author":"X Wen","year":"2022","unstructured":"Wen X, Xu P, Shi M, Liu J, Zeng X, Zhang Y, et al. Evans blue-modified radiolabeled fibroblast activation protein inhibitor as long-acting cancer therapeutics. Theranostics. 2022;12:422\u201333. https:\/\/doi.org\/10.7150\/thno.68182.","journal-title":"Theranostics"},{"key":"7155_CR6","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1039\/c5cs00158g","volume":"45","author":"Z Liu","year":"2016","unstructured":"Liu Z, Chen X. Simple bioconjugate chemistry serves great clinical advances: albumin as a versatile platform for diagnosis and precision therapy. Chem Soc Rev. 2016;45:1432\u201356. https:\/\/doi.org\/10.1039\/c5cs00158g.","journal-title":"Chem Soc Rev"},{"key":"7155_CR7","doi-asserted-by":"publisher","first-page":"3213","DOI":"10.1021\/acs.bioconjchem.8b00556","volume":"29","author":"Z Wang","year":"2018","unstructured":"Wang Z, Tian R, Niu G, Ma Y, Lang L, Szajek LP, et al. Single low-dose injection of Evans Blue Modified PSMA-617 Radioligand Therapy Eliminates Prostate-Specific Membrane Antigen Positive Tumors. Bioconjug Chem. 2018;29:3213\u201321. https:\/\/doi.org\/10.1021\/acs.bioconjchem.8b00556.","journal-title":"Bioconjug Chem"},{"key":"7155_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.apsb.2024.05.022","author":"W Guo","year":"2024","unstructured":"Guo W, Wen X, Chen Y, Zhao T, Liu J, Tao Y, et al. Safety, dosimetry, and efficacy of an optimized long-acting somatostatin analog for peptide receptor radionuclide therapy in metastatic neuroendocrine tumors: from preclinical testing to first-in-human study. Acta Pharm Sinica B. 2024. https:\/\/doi.org\/10.1016\/j.apsb.2024.05.022.","journal-title":"Acta Pharm Sinica B"},{"key":"7155_CR9","doi-asserted-by":"publisher","first-page":"2846","DOI":"10.1007\/s00259-023-06229-w","volume":"50","author":"X Wen","year":"2023","unstructured":"Wen X, Xu P, Zeng X, Liu J, Du C, Zeng X, et al. Development of [(177)Lu]Lu-LNC1003 for radioligand therapy of prostate cancer with a moderate level of PSMA expression. Eur J Nucl Med Mol Imaging. 2023;50:2846\u201360. https:\/\/doi.org\/10.1007\/s00259-023-06229-w.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7155_CR10","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1007\/s00259-023-06470-3","volume":"51","author":"J Zang","year":"2024","unstructured":"Zang J, Wang G, Zhao T, Liu H, Lin X, Yang Y, et al. A phase 1 trial to determine the maximum tolerated dose and patient-specific dosimetry of [(177)Lu]Lu-LNC1003 in patients with metastatic castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2024;51:871\u201382. https:\/\/doi.org\/10.1007\/s00259-023-06470-3.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7155_CR11","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.2967\/jnumed.116.178673","volume":"57","author":"C Kratochwil","year":"2016","unstructured":"Kratochwil C, Bruchertseifer F, Giesel FL, Weis M, Verburg FA, Mottaghy F, et al. 225Ac-PSMA-617 for PSMA-Targeted \u03b1-Radiation Therapy of Metastatic Castration-resistant prostate Cancer. J Nucl Med. 2016;57:1941\u20134. https:\/\/doi.org\/10.2967\/jnumed.116.178673.","journal-title":"J Nucl Med"},{"key":"7155_CR12","doi-asserted-by":"publisher","first-page":"1034315","DOI":"10.3389\/fmed.2022.1034315","volume":"9","author":"M Shi","year":"2022","unstructured":"Shi M, Jakobsson V, Greifenstein L, Khong PL, Chen X, Baum RP, et al. Alpha-peptide receptor radionuclide therapy using actinium-225 labeled somatostatin receptor agonists and antagonists. Front Med (Lausanne). 2022;9:1034315. https:\/\/doi.org\/10.3389\/fmed.2022.1034315.","journal-title":"Front Med (Lausanne)"},{"key":"7155_CR13","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/s1470-2045(23)00529-6","volume":"25","author":"MS Hofman","year":"2024","unstructured":"Hofman MS, Emmett L, Sandhu S, Iravani A, Buteau JP, Joshua AM, et al. Overall survival with [(177)Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial. Lancet Oncol. 2024;25:99\u2013107. https:\/\/doi.org\/10.1016\/s1470-2045(23)00529-6.","journal-title":"Lancet Oncol"},{"key":"7155_CR14","doi-asserted-by":"publisher","first-page":"2969","DOI":"10.7150\/thno.96403","volume":"14","author":"AP Bidkar","year":"2024","unstructured":"Bidkar AP, Zerefa L, Yadav S, VanBrocklin HF, Flavell RR. Actinium-225 targeted alpha particle therapy for prostate cancer. Theranostics. 2024;14:2969\u201392. https:\/\/doi.org\/10.7150\/thno.96403.","journal-title":"Theranostics"},{"key":"7155_CR15","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/j.eururo.2023.12.004","volume":"85","author":"KN Chi","year":"2024","unstructured":"Chi KN, Armstrong AJ, Krause BJ, Herrmann K, Rahbar K, de Bono JS, et al. Safety analyses of the phase 3 VISION trial of [(177)Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate Cancer. Eur Urol. 2024;85:382\u201391. https:\/\/doi.org\/10.1016\/j.eururo.2023.12.004.","journal-title":"Eur Urol"},{"key":"7155_CR16","doi-asserted-by":"publisher","first-page":"989","DOI":"10.2967\/jnumed.120.256263","volume":"62","author":"AD Stuparu","year":"2021","unstructured":"Stuparu AD, Capri JR, Meyer CAL, Le TM, Evans-Axelsson SL, Current K, et al. Mechanisms of resistance to prostate-specific membrane Antigen-targeted Radioligand Therapy in a mouse model of prostate Cancer. J Nucl Med. 2021;62:989\u201395. https:\/\/doi.org\/10.2967\/jnumed.120.256263.","journal-title":"J Nucl Med"},{"key":"7155_CR17","doi-asserted-by":"publisher","unstructured":"Sallam M, Nguyen NT, Sainsbury F, Kimizuka N, Muyldermans S, Bene\u0161ov\u00e1-Sch\u00e4fer M. PSMA-targeted radiotheranostics in modern nuclear medicine: then, now, and what of the future? Theranostics. 2024;14:3043\u201379. https:\/\/doi.org\/10.7150\/thno.92612","DOI":"10.7150\/thno.92612"},{"key":"7155_CR18","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1007\/s00259-018-4096-y","volume":"46","author":"J Zang","year":"2019","unstructured":"Zang J, Fan X, Wang H, Liu Q, Wang J, Li H, et al. First-in-human study of (177)Lu-EB-PSMA-617 in patients with metastatic castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2019;46:148\u201358. https:\/\/doi.org\/10.1007\/s00259-018-4096-y.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7155_CR19","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.2967\/jnumed.121.263618","volume":"63","author":"M Sathekge","year":"2022","unstructured":"Sathekge M, Bruchertseifer F, Vorster M, Lawal IO, Knoesen O, Mahapane J, et al. mCRPC patients receiving 225Ac-PSMA-617 therapy in the post\u2013androgen deprivation therapy setting: response to treatment and survival analysis. J Nucl Med. 2022;63:1496\u2013502. https:\/\/doi.org\/10.2967\/jnumed.121.263618.","journal-title":"J Nucl Med"},{"key":"7155_CR20","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1200\/jco.23.00573","volume":"42","author":"ST Tagawa","year":"2024","unstructured":"Tagawa ST, Thomas C, Sartor AO, Sun M, Stangl-Kremser J, Bissassar M, et al. Prostate-specific membrane Antigen-Targeting Alpha Emitter via antibody delivery for metastatic castration-resistant prostate Cancer: a phase I dose-escalation study of (225)Ac-J591. J Clin Oncol. 2024;42:842\u201351. https:\/\/doi.org\/10.1200\/jco.23.00573.","journal-title":"J Clin Oncol"},{"key":"7155_CR21","doi-asserted-by":"publisher","first-page":"669","DOI":"10.2967\/jnumed.120.251017","volume":"62","author":"MJ Zacherl","year":"2021","unstructured":"Zacherl MJ, Gildehaus FJ, Mittlmeier L, B\u00f6ning G, Gosewisch A, Wenter V, et al. First clinical results for PSMA-Targeted \u03b1-Therapy using (225)Ac-PSMA-I&T in Advanced-mCRPC patients. J Nucl Med. 2021;62:669\u201374. https:\/\/doi.org\/10.2967\/jnumed.120.251017.","journal-title":"J Nucl Med"},{"key":"7155_CR22","doi-asserted-by":"publisher","first-page":"7203","DOI":"10.7150\/thno.78043","volume":"12","author":"F Reissig","year":"2022","unstructured":"Reissig F, Zarschler K, Novy Z, Petrik M, Bendova K, Kurfurstova D, et al. Modulating the pharmacokinetic profile of Actinium-225-labeled macropa-derived radioconjugates by dual targeting of PSMA and albumin. Theranostics. 2022;12:7203\u201315. https:\/\/doi.org\/10.7150\/thno.78043.","journal-title":"Theranostics"},{"key":"7155_CR23","doi-asserted-by":"publisher","first-page":"13429","DOI":"10.1021\/acs.jmedchem.1c00772","volume":"64","author":"S Iikuni","year":"2021","unstructured":"Iikuni S, Tarumizu Y, Nakashima K, Higaki Y, Ichikawa H, Watanabe H, et al. Radiotheranostics using a Novel (225)Ac-Labeled Radioligand with Improved Pharmacokinetics Targeting prostate-specific membrane Antigen. J Med Chem. 2021;64:13429\u201338. https:\/\/doi.org\/10.1021\/acs.jmedchem.1c00772.","journal-title":"J Med Chem"},{"key":"7155_CR24","doi-asserted-by":"publisher","first-page":"980","DOI":"10.2967\/jnumed.120.256388","volume":"62","author":"SR Banerjee","year":"2021","unstructured":"Banerjee SR, Lisok A, Minn I, Josefsson A, Kumar V, Brummet M, et al. Preclinical evaluation of (213)Bi- and (225)Ac-Labeled low-molecular-weight compounds for Radiopharmaceutical Therapy of prostate Cancer. J Nucl Med. 2021;62:980\u20138. https:\/\/doi.org\/10.2967\/jnumed.120.256388.","journal-title":"J Nucl Med"},{"key":"7155_CR25","doi-asserted-by":"publisher","unstructured":"Ocak M, Toklu T, Demirci E, Sel\u00e7uk N, Kabasakal L. Post-therapy imaging of 225Ac-DOTATATE treatment in a patient with recurrent neuroendocrine tumor. Eur J Nucl Med Mol Imaging.2020;47:2711-2. https:\/\/doi.org\/10.1007\/s00259-020-04725-x.","DOI":"10.1007\/s00259-020-04725-x"},{"key":"7155_CR26","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1007\/s00259-019-04567-2","volume":"47","author":"S Ballal","year":"2020","unstructured":"Ballal S, Yadav MP, Bal C, Sahoo RK, Tripathi M. Broadening horizons with (225)Ac-DOTATATE targeted alpha therapy for gastroenteropancreatic neuroendocrine tumour patients stable or refractory to (177)Lu-DOTATATE PRRT: first clinical experience on the efficacy and safety. Eur J Nucl Med Mol Imaging. 2020;47:934\u201346. https:\/\/doi.org\/10.1007\/s00259-019-04567-2.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7155_CR27","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1007\/s00259-002-1054-4","volume":"30","author":"WA Breeman","year":"2003","unstructured":"Breeman WA, van der Wansem K, Bernard BF, van Gameren A, Erion JL, Visser TJ, et al. The addition of DTPA to [177Lu-DOTA0,Tyr3]octreotate prior to administration reduces rat skeleton uptake of radioactivity. Eur J Nucl Med Mol Imaging. 2003;30:312\u20135. https:\/\/doi.org\/10.1007\/s00259-002-1054-4.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7155_CR28","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1021\/acs.bioconjchem.2c00190","volume":"33","author":"KJ Kadassery","year":"2022","unstructured":"Kadassery KJ, King AP, Fayn S, Baidoo KE, MacMillan SN, Escorcia FE, et al. H(2)BZmacropa-NCS: a bifunctional Chelator for Actinium-225 targeted alpha therapy. Bioconjug Chem. 2022;33:1222\u201331. https:\/\/doi.org\/10.1021\/acs.bioconjchem.2c00190.","journal-title":"Bioconjug Chem"},{"key":"7155_CR29","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.2967\/jnumed.123.266894","volume":"65","author":"CW Wichmann","year":"2024","unstructured":"Wichmann CW, Morgan KA, Cao Z, Osellame LD, Guo N, Gan H, et al. Radiolabeling and preclinical evaluation of therapeutic efficacy of 225Ac-ch806 in Glioblastoma and Colorectal Cancer Xenograft models. J Nucl Med. 2024;65:1456\u201362. https:\/\/doi.org\/10.2967\/jnumed.123.266894.","journal-title":"J Nucl Med"},{"key":"7155_CR30","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.2967\/jnumed.118.214379","volume":"59","author":"T Langbein","year":"2018","unstructured":"Langbein T, Chauss\u00e9 G, Baum RP. Salivary gland toxicity of PSMA Radioligand Therapy: relevance and preventive strategies. J Nucl Med. 2018;59:1172\u20133. https:\/\/doi.org\/10.2967\/jnumed.118.214379.","journal-title":"J Nucl Med"},{"key":"7155_CR31","doi-asserted-by":"publisher","unstructured":"Heynickx N, Herrmann K, Vermeulen K, Baatout S, Aerts A. The salivary glands as a dose limiting organ of PSMA- targeted radionuclide therapy: a review of the lessons learnt so far. Nucl Med Biol. 2021;98\u20139. https:\/\/doi.org\/10.1016\/j.nucmedbio.2021.04.003.","DOI":"10.1016\/j.nucmedbio.2021.04.003"},{"key":"7155_CR32","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.3390\/diagnostics12081926","volume":"12","author":"T Langbein","year":"2022","unstructured":"Langbein T, Kulkarni HR, Schuchardt C, Mueller D, Volk GF, Baum RP. Salivary gland toxicity of PSMA-Targeted Radioligand Therapy with (177)Lu-PSMA and Combined (225)Ac- and (177)Lu-Labeled PSMA ligands (TANDEM-PRLT) in advanced prostate Cancer: a single-center systematic investigation. Diagnostics (Basel). 2022;12:1926. https:\/\/doi.org\/10.3390\/diagnostics12081926.","journal-title":"Diagnostics (Basel)"},{"key":"7155_CR33","doi-asserted-by":"publisher","first-page":"6179","DOI":"10.7150\/thno.76571","volume":"12","author":"HT Kuo","year":"2022","unstructured":"Kuo HT, Lin KS, Zhang Z, Zhang C, Merkens H, Tan R, et al. What a difference a methylene makes: replacing glu with asp or aad in the lys-urea-glu pharmacophore of PSMA-targeting radioligands to reduce kidney and salivary gland uptake. Theranostics. 2022;12:6179\u201388. https:\/\/doi.org\/10.7150\/thno.76571.","journal-title":"Theranostics"},{"key":"7155_CR34","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1007\/s13139-017-0508-3","volume":"52","author":"RP Baum","year":"2018","unstructured":"Baum RP, Langbein T, Singh A, Shahinfar M, Schuchardt C, Volk GF, et al. Injection of Botulinum Toxin for preventing salivary gland toxicity after PSMA Radioligand Therapy: an empirical proof of a Promising Concept. Nucl Med Mol Imaging. 2018;52:80\u20131. https:\/\/doi.org\/10.1007\/s13139-017-0508-3.","journal-title":"Nucl Med Mol Imaging"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07155-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-025-07155-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07155-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T05:22:54Z","timestamp":1749705774000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-025-07155-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,24]]},"references-count":34,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["7155"],"URL":"https:\/\/doi.org\/10.1007\/s00259-025-07155-9","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,24]]},"assertion":[{"value":"31 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Animal experiments were approved by the animal care committee of Yantai Lannacheng Biotechnology Co., Ltd. (ID LNCD-20240218 (01)) and carried out in compliance with the national laws related to the conduct of animal experimentation. This article does not contain any studies with human participants performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"X.C. is a co-founder of and holds shares in Yantai Lannacheng Biotechnology Co., Ltd. No other potential conflict of interest relevant to this article was reported.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interes"}}]}}